Cargando…

Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media

The poor solubility and permeability of compounds beyond Lipinski’s Rule of Five (bRo5) are major challenges for cell-based permeability assays. Due to their incompatibility with gastrointestinal components in biorelevant media, the exploration of important questions addressing food effects is limit...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Dong, López Mármol, Álvaro, Lenz, Verena, Muschong, Patricia, Wilhelm-Alkubaisi, Anita, Weinheimer, Manuel, Koziolek, Mirko, Sauer, Kerstin A., Laplanche, Loic, Mezler, Mario
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032137/
https://www.ncbi.nlm.nih.gov/pubmed/35456533
http://dx.doi.org/10.3390/pharmaceutics14040699
_version_ 1784692566954868736
author Ye, Dong
López Mármol, Álvaro
Lenz, Verena
Muschong, Patricia
Wilhelm-Alkubaisi, Anita
Weinheimer, Manuel
Koziolek, Mirko
Sauer, Kerstin A.
Laplanche, Loic
Mezler, Mario
author_facet Ye, Dong
López Mármol, Álvaro
Lenz, Verena
Muschong, Patricia
Wilhelm-Alkubaisi, Anita
Weinheimer, Manuel
Koziolek, Mirko
Sauer, Kerstin A.
Laplanche, Loic
Mezler, Mario
author_sort Ye, Dong
collection PubMed
description The poor solubility and permeability of compounds beyond Lipinski’s Rule of Five (bRo5) are major challenges for cell-based permeability assays. Due to their incompatibility with gastrointestinal components in biorelevant media, the exploration of important questions addressing food effects is limited. Thus, we established a robust mucin-protected Caco-2 assay to allow the assessment of drug permeation in complex biorelevant media. To do that, the assay conditions were first optimized with dependence of the concentration of porcine mucin added to the cells. Mucin-specific effects on drug permeability were evaluated by analyzing cell permeability values for 15 reference drugs (BCS class I–IV). Secondly, a sigmoidal relationship between mucin-dependent permeability and fraction absorbed in human (f(a)) was established. A case study with venetoclax (BCS class IV) was performed to investigate the impact of medium complexity and the prandial state on drug permeation. Luminal fluids obtained from the tiny-TIM system showed a higher solubilization capacity for venetoclax, and a better read-out for the drug permeability, as compared to FaSSIF or FeSSIF media. In conclusion, the mucin-protected Caco-2 assay combined with biorelevant media improves the mechanistic understanding of drug permeation and addresses complex biopharmaceutical questions, such as food effects on oral drug absorption.
format Online
Article
Text
id pubmed-9032137
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90321372022-04-23 Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media Ye, Dong López Mármol, Álvaro Lenz, Verena Muschong, Patricia Wilhelm-Alkubaisi, Anita Weinheimer, Manuel Koziolek, Mirko Sauer, Kerstin A. Laplanche, Loic Mezler, Mario Pharmaceutics Article The poor solubility and permeability of compounds beyond Lipinski’s Rule of Five (bRo5) are major challenges for cell-based permeability assays. Due to their incompatibility with gastrointestinal components in biorelevant media, the exploration of important questions addressing food effects is limited. Thus, we established a robust mucin-protected Caco-2 assay to allow the assessment of drug permeation in complex biorelevant media. To do that, the assay conditions were first optimized with dependence of the concentration of porcine mucin added to the cells. Mucin-specific effects on drug permeability were evaluated by analyzing cell permeability values for 15 reference drugs (BCS class I–IV). Secondly, a sigmoidal relationship between mucin-dependent permeability and fraction absorbed in human (f(a)) was established. A case study with venetoclax (BCS class IV) was performed to investigate the impact of medium complexity and the prandial state on drug permeation. Luminal fluids obtained from the tiny-TIM system showed a higher solubilization capacity for venetoclax, and a better read-out for the drug permeability, as compared to FaSSIF or FeSSIF media. In conclusion, the mucin-protected Caco-2 assay combined with biorelevant media improves the mechanistic understanding of drug permeation and addresses complex biopharmaceutical questions, such as food effects on oral drug absorption. MDPI 2022-03-24 /pmc/articles/PMC9032137/ /pubmed/35456533 http://dx.doi.org/10.3390/pharmaceutics14040699 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ye, Dong
López Mármol, Álvaro
Lenz, Verena
Muschong, Patricia
Wilhelm-Alkubaisi, Anita
Weinheimer, Manuel
Koziolek, Mirko
Sauer, Kerstin A.
Laplanche, Loic
Mezler, Mario
Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media
title Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media
title_full Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media
title_fullStr Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media
title_full_unstemmed Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media
title_short Mucin-Protected Caco-2 Assay to Study Drug Permeation in the Presence of Complex Biorelevant Media
title_sort mucin-protected caco-2 assay to study drug permeation in the presence of complex biorelevant media
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9032137/
https://www.ncbi.nlm.nih.gov/pubmed/35456533
http://dx.doi.org/10.3390/pharmaceutics14040699
work_keys_str_mv AT yedong mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT lopezmarmolalvaro mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT lenzverena mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT muschongpatricia mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT wilhelmalkubaisianita mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT weinheimermanuel mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT koziolekmirko mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT sauerkerstina mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT laplancheloic mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia
AT mezlermario mucinprotectedcaco2assaytostudydrugpermeationinthepresenceofcomplexbiorelevantmedia